Table 1.
Demographics and baseline characteristics, efficacy population
| Total (n = 719) | <75 years (n = 527) | ≥75 years (n = 192) | |
|---|---|---|---|
| Age (years), mean (SD) | 66.2 (12.3) | 61.5 (10.8) | 79.3 (3.4) |
| Range | 21–89 | 21–74 | 75–89 |
| Sex, n (%) | |||
| Female | 411 (57.2) | 309 (58.6) | 102 (53.1) |
| Male | 308 (42.8) | 218 (41.4) | 90 (46.9) |
| Race, n (%) | |||
| Caucasian | 637 (88.6) | 462 (87.7) | 175 (91.1) |
| Other | 82 (11.4) | 65 (12.3) | 17 (8.9) |
| Weight (kg), mean (SD) | 81.2 (17.9) | 82.4 (18.9) | 78.1 (14.6) |
| BMI (kg/m2), mean (SD) | 28.8 (5.6) | 29.1 (5.9) | 27.9 (4.7) |
| Creatinine clearancea,b (ml/min) | |||
| Mean (SD) | 87.5 (44.0) | 95.6 (48.0) | 65.4 (13.7) |
| <80 ml/min, n (%) | 349 (48.5) | 189 (35.9) | 160 (83.3) |
| ≥80 ml/min, n (%) | 352 (49.0) | 322 (61.1) | 30 (15.6) |
| Average Daily Pain Score | |||
| Mean (SD) | 6.5 (1.4) | 6.4 (1.4) | 6.8 (1.4) |
| Months since HZ resolutionb, mean (SD) | 27.9 (36.0) | 26.1 (36.9) | 32.8 (32.8) |
| <6 months, n (%) | 68 (9.5) | 54 (10.2) | 14 (7.3) |
| 6–12 months, n (%) | 197 (27.4) | 157 (29.8) | 40 (20.8) |
| >12 months, n (%) | 449 (62.4) | 311 (59.0) | 138 (71.9) |
| Location of neuropathic painc, n (%) | |||
| Face | 152 (21.1) | 104 (19.7) | 48 (25.0) |
| Anterior torso | 291 (40.5) | 218 (41.4) | 73 (38.0) |
| Posterior torso | 295 (41.0) | 218 (41.4) | 77 (40.1) |
| Arms | 68 (9.5) | 44 (8.3) | 24 (12.5) |
| Legs | 49 (6.8) | 35 (6.6) | 14 (7.3) |
| Other | 150 (20.9) | 119 (22.6) | 31 (16.1) |
aCreatinine clearance as calculated by the Cockroft–Gault method
bData not available for some patients
cPatients may be reported in more than one category
BMI body mass index, SD standard deviation, HZ herpes zoster